This segment focuses on the research, development, and commercialization of innovative drugs for various cancers. Research and development activities include the discovery and preclinical development of small molecule and recombinant protein drugs. The company utilizes advanced technologies such as deuteration and targeted therapies. This segment addresses significant unmet needs in oncology, aiming to improve patient outcomes and survival rates. Market positioning is based on innovation and a focus on the Chinese market. Future opportunities include expanding the product pipeline and entering new therapeutic areas. Regulatory and clinical aspects involve conducting clinical trials and obtaining regulatory approvals in China and other regions. Partnerships and collaborations are pursued to accelerate drug development and commercialization.

This segment concentrates on developing and commercializing drugs for hepatobiliary diseases and hemorrhage. Research and development efforts involve creating small molecule and recombinant protein drugs to address conditions like liver cancer and other hepatobiliary disorders. The company employs various technologies, including those related to small molecule drug development and protein engineering. The segment aims to improve the treatment of these diseases, offering new therapeutic options and improving patient outcomes. Market positioning is based on addressing specific unmet needs in the Chinese healthcare market. Future opportunities include expanding the product portfolio and exploring new indications. Regulatory and clinical aspects involve conducting clinical trials and obtaining regulatory approvals. Partnerships and collaborations are essential for accelerating drug development and market access.